Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool January 9, 2007 Billy Fisher	St. Jude's Juiced-Up Q4 The medical-device maker shows stronger vital signs. Investors, take note.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
The Motley Fool July 20, 2005 Stephen D. Simpson	Hey, Jude! Party Hearty St. Jude's ICD (implantable cardioverter defibrillator) business is on fire and fueling strong profit growth for this medical device maker. Whether your cut-off makes St. Jude a mid-cap or a large-cap, this company is certainly growing -- and the stock's valuation reflects that.
The Motley Fool October 19, 2007 Billy Fisher	Keeping Pace at St. Jude Medical device maker St. Jude Medical has a strong quarter, but investors weren't impressed.
The Motley Fool January 26, 2005 Stephen D. Simpson	St. Jude Is No Lost Cause The No. 3 cardiology company posts solid growth because of continuing implantable cardioverter defibrillator (ICD) market share gains.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool February 17, 2009 Brian Orelli	Investors Heart Medtronic The leaner company is more lovable.
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool February 22, 2006 Stephen D. Simpson	Medtronic's Minor Miss Sluggish sales in several market categories might spook investors.
The Motley Fool November 18, 2004 W.D. Crotty	Medtronic Down, Not Out Internal defibrillator maker's earnings growth rate is slowing down, but its future looks healthy.
The Motley Fool May 24, 2006 S.J. Caplan	Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note.
BusinessWeek March 22, 2004 Robert Barker	St. Jude: An Insider Sign To Investors? St. Jude, the patron saint of lost causes, rarely has needed to look out for his namesake, St. Jude Medical (STJ ). Since its birth in 1976, this maker of artificial heart valves, defibrillators, catheters, and sundry other cardiac devices has led a blessed life. It's in excellent health today. So why are insiders dumping the stock?
The Motley Fool February 8, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Dominion Resources... Goodrich Petroleum... iPass... ITT Educational Services... St. Jude Medical...
The Motley Fool July 25, 2011 Jason Moser	Rising Star Buy: St. Jude Medical It's a good time to jump in on this medical-device maker.
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool August 18, 2005 Stephen D. Simpson	Medtronic Keeps the Beat Strong growth in the ICD and spinal businesses keep Medtronic running. The stock is trading more or less at par to the market with respect to its P/E-to-growth ratio. Investors must decide for themselves whether that's a fair price to pay.
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool April 18, 2006 Stephen D. Simpson	Get Ready for the New Boston Scientific Here's hoping it does a better job as a bigger business. For all of the risks that are present, there still could be rewards here for investors.
The Motley Fool April 11, 2008 Brian Orelli	St. Jude's Heartfelt Acquisition Medical-device maker St. Jude purchases tiny EP MedSystems.
The Motley Fool April 9, 2010 Brian Orelli	Is Boston Scientific Turning It Around? Selling off a pair of units could help.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool April 23, 2011	St. Jude, Medtronic Execs Offer Different Views on JAMA Article's Impact An article and government investigation into implant devices may or may not have played a role in each company's performance, depending on whom you ask.
The Motley Fool April 25, 2011 Arundhati Parmar	St. Jude: New Aortic Replacement Valve Approved St. Jude gets good news.
The Motley Fool March 16, 2010 Brian Orelli	No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool February 26, 2008 Brian Orelli	Quick Take: Boston Scientific Gets Approved -- Thrice The medical device maker is granted three FDA approvals in one day.
The Motley Fool July 25, 2011 Jordan DiPietro	Should You Retire With St. Jude? I can't decide for you whether or not this is the best stock for retirement, but it has passed all four tests, which is pretty impressive.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool February 23, 2006 Stephen D. Simpson	A Nasty Jolt to Greatbatch Disappointing margins take a bite out of the company's market cap. While valuation here is a bit difficult, any way you slice it, the stock doesn't look too interesting.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?
The Motley Fool August 23, 2006 Stephen D. Simpson	Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool September 29, 2010 Brian Orelli	Boston Scientific: Strengths, Weaknesses, Opportunities, Threats One of the best ways to develop a picture of any company is with the SWOT analysis -- a look at a company's strengths, weaknesses, opportunities, and threats. Let's take a look at Boston Scientific in this light as it tries to turn itself around.
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool June 20, 2005 Stephen D. Simpson	Ouch! Guidant Zaps Itself Problems with ICDs have led to a voluntary recall and could fuel a class action suit. While Guidant is doing the right thing now, investors, patients, and doctors may well ask whether more should have been done sooner.
The Motley Fool April 27, 2010 Brian Orelli	Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless.
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool May 25, 2011 Brian Orelli	No Red Carpet for Medtronic's New CEO Omar Ishrak, Medtronic's newly-appointed CEO, looks like he has his work cut out for him trying to get the medical-device maker growing again.